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Neuroblastoma (NBL) is the most common extra-cranial tumour in childhood. It can present as an abdominal mass, but
is usually metastatic at diagnosis so the symptomatology can be varied. Nephroblastoma, also more commonly known
as a Wilms tumour, is the commonest renal tumour in childhood and more typically presents as abdominal pathology
with few constitutional symptoms, although rarely haematuria can be a presenting feature. The pathophysiology and
clinical aspects of both tumours including associated risk factors and pathologies are discussed. Oncogenetics and
chromosomal abnormalities are increasingly recognised as important prognostic indicators and their impact on initial
management is considered. Imaging plays a pivotal role in terms of diagnosis and recent imaging advances mean
that radiology has an increasingly crucial role in the management pathway. The use of image defined risk factors
in neuroblastoma has begun to dramatically change how this tumour is characterised pre-operatively. The National
Wilms Tumour Study Group have comprehensively staged Wilms tumours and this is reviewed as it impacts significantly
on management. The use of contrast-enhanced MRI and diffusion-weighted sequences have further served to augment
the information available to the clinical team during initial assessment of both neuroblastomas and Wilms tumours. The
differences in management strategies are outlined. This paper therefore aims to provide a comprehensive update on
these two common paediatric tumours with a particular emphasis on the current crucial role played by imaging.
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Neuroblastoma (NBL) is the most common extra-cranial
tumour in childhood. It can present as an abdominal
mass, but it is often metastatic at diagnosis, so can
manifest in a variety of other ways often in an unwell
child. Nephroblastoma, also more commonly known as
a Wilms tumour, is the commonest renal tumour in
childhood and more typically presents as abdominal
pathology in an otherwise asymptomatic patient. The
natural histories and typical clinical courses of these
common tumours are very different. This paper reviews
the clinical aspects and imaging characteristics of both
tumours, summarising the key differences to aid the
paediatrician and radiologist in their diagnosis and
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Neuroblastoma
Background
Neuroblastoma (NBL) is the most common solid extra-
cranial tumour in childhood [1]. NBL arises from primor-
dial neural crest cells that form the sympathetic nervous
system, occurring anywhere along the sympathetic ner-
vous system chain [1,2]. Under the microscope, they are
small, round, blue cells that are clustered in rosettes. They
share similar cell characteristics on gross histological
evaluation to other relatively common paediatric tumours
such as Ewing’s sarcoma, primitive neuroectodermal tu-
mours (PNETs), leukaemia, lymphoma and rhabdomyo-
sarcoma [3].
Typically, NBLs occur in early childhood with up to
90% diagnosed by 6 years of age [4]. Incidence is slightly
higher in Caucasians. The heterogeneity of the tumour,
and its biological characteristics, mean the prognosis is
highly variable at different ages. Some behave aggres-
sively while others, typically in infancy, may spontan-
eously regress. This variability means survival rates also. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Dumba et al. Cancer Imaging  (2015) 15:5 Page 2 of 14differ. Low to intermediate risk tumours tend to have a
reasonably good prognosis (90% survival approximately)
with high-risk tumours being much less favourable (40-
50% survival) [5]. In 2002, approximately 15% of child-
hood cancer deaths were due to NBL [6].
Associations and risk factors
The vast majority of cases are sporadic. Approximately 1%
are familial, displaying an autosomal dominant pattern of
inheritance with incomplete penetrance [1,4]. There are a
wide number of conditions that have been associated with
NBL; neurofibromatosis type 1, Beckwith-Weidemann
syndrome, Hirschsprung’s disease and DiGeorge syn-
drome are all described in the literature [6].
NBLs have a variable prognosis; tumour stage, patient
age, tumour oncogenes and DNA content are all known
to be implicated. The MYCN oncogene is responsible
for providing the code used by proteins in tissue devel-
opment. If this mutates, which can be signalled by ab-
normal amplification, cancerous cells can develop and
the resulting mass is more resistant to treatment, thus it
has a more unfavourable outcome [1]. This negative fea-
ture occasionally includes those children who otherwise
have favourable tumour presentation features, for ex-
ample 4S/MS disease and young age [1]. Tumours with
MYCN amplification, whether localised or metastatic,
are all categorised as high risk tumours in both North
American Children's Oncology Group (COG) and
European (SIOPEN) neuroblastoma studies. NBL with
DNA that has a hyperdiploid structure appears to be
less aggressive. This is thought to be secondary to a re-
duction in mitosis [1].
Other markers which can affect management include
chromosomes and nerve receptors. Alterations in two
chromosomes, namely a deletion on the short arm of
chromosome 1 (1p) seen in around a quarter of NBLs,
and deletion of chromosome 11q have a poorer progno-
sis [1]. Although 1p deletion is associated with MCYN
amplification, 11q is not correlated and appears to have
separate negative prognostic factors. TrkA is a neurotro-
phin receptor that may actually be associated with an
improved prognosis.
Clinical features
Presenting features are diverse and very much dependent
on the anatomical location of the tumour. Most com-
monly, NBLs are located within the adrenal gland, but can
be found in sympathetic ganglia of the retroperitoneum,
posterior mediastinum, neck or pelvis [1]. The organ of
Zuckerkandl is a mass of neural crest tissue adjacent to
the mid to distal abdominal aorta and it is another recog-
nized site of disease.
Abdominal masses usually cause pain due to their
mass effect, as well as abdominal distension [6]. Theyoften grow to a large size before causing problems, so a
palpable mass on presentation is common. Abdominal
masses can also compress renal vessels resulting in
hypertension being a presenting feature. Thoracic NBL
may present with airway compromise, scoliosis or as an
incidental finding on chest x-ray. The biology of thoracic
NBL tends to be less aggressive than with abdominal
disease and as such the prognosis tends to be more
favourable.
Paraneoplastic syndromes may be associated with non-
metastatic disease. One of these syndromes is opsomyo-
clonus, complicating 2-4% of presentations [1,6]. The
other is the excessive production of vasoactive intestinal
peptide (VIP) resulting in watery diarrhoea and failure to
thrive [1]. In addition to local disease, metastatic disease
complicates 50% of all presentations. Common sites of
metastases include liver, lymph nodes and bone marrow
[1]. NBLs can metastasize to the skull base and orbital
floor resulting in periorbital ecchymoses and a so-called
“raccoon eye” appearance [1,3].
Diagnosis
Plain films are non-specific for NBL and are largely un-
helpful in the diagnostic pathway. Tumours of the chest
and neck can be incidentally picked up on radiographs
performed for other reasons [Figure 1]. Features that are
suggestive of thoracic disease include abnormalities of
the normal silhouettes typically seen on chest x-rays.
The right and left paraspinal lines are where the lung or
pleura interacts with the mediastinal soft tissues. In chil-
dren, the paraspinal lines are less frequently observed
than in adults due to less mediastinal fat and no aortic
ectasia. Thickening and irregularity of these lines, in par-
ticular the right paraspinal line which is not normally
seen in healthy children, can indicate the presence of in-
creased mediastinal soft tissue and this warrants further
investigation [7].
Ultrasound (US) is often the first line investigation in
paediatrics, particularly for those presenting with an ab-
dominal mass. NBLs appear as solid, heterogeneous
masses with calcification, but are rarely cystic on US [8].
For surgical planning and risk stratification, more de-
tailed cross-sectional imaging is necessary.
MRI should now be the cornerstone imaging modality
for all primary NBL tumours [Figure 2], whether in the
neck, chest, abdomen or pelvis. MRI can easily assess
the extent of disease, being superior to CT in assessing
metastatic marrow disease, chest wall invasion and
spinal canal involvement [Figures 3, 4 & 5]. CT should
ideally now, in our opinion, be reserved for pre-
operative surgical planning, particularly if there is a sur-
gical preference for CT, when contrast-enhanced images
can delineate the vasculature to best effect [1]. With fi-
brosis and calcification developing after chemotherapy,
Figure 1 Chest x-ray of 3 year old girl showing thoracic NBL. Note erosions of the posterior 3rd and 4th ribs indicating a posterior
mediastinal mass.
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images. The full extent of the mass can be difficult to
define on a pre-operative MRI scan and thus make sur-
gical planning more challenging. On a CT study post-
chemotherapy, the solid portions of the mass are easier
to define than on MRI and the extent of calcification,
which increases after treatment and which can be im-
portant for the surgeon to appreciate before surgery, is
more easily characterised. These features are particularly
important when the mass is known to be encasing major
vessels. In more localised adrenal or other L1 tumours,
pre-operative MRI is preferred over CT as no significant
vascular encasement is typically present. On MR at diag-
nosis, the tumour tends to return low signal on T1-
weighted sequences with high signal on T2 [3]. Areas of
calcification and haemorrhage can also be detected, the
former less reliably [3]. Variable contrast-enhancement
may be seen, with the more malignant tumours show-
ing restricted diffusion on diffusion-weighted imaging
(DWI). On CT, NBLs are poorly marginated, heteroge-
neous masses. They can demonstrate extension across
the midline and into adjacent body cavities. One of the
key defining features is the presence of calcification
[Figure 6] seen in 80-90% of CT studies [2]. Despite
their size and sometimes aggressive nature, NBLs tend
to encase and displace structures rather than invade
them [Figure 3]. Vascular invasion is not a classic fea-
ture demonstrated on cross-sectional imaging [2].
Nuclear medicine studies are utilised in the diagnostic
pathway to detect occult disease and assess for distantbony spread. Metaiodobenzylguanidine (MIBG) scintig-
raphy [Figure 7] is sensitive and specific for NBL be-
cause, despite being taken up by other neuroendocrine
tumours, these other tumours are extremely rare in the
younger paediatric population [3]. Over 90% are MIBG-
sensitive, but for those primary tumours that are not
MIBG avid, 99mTc-diphosphonate bone scintigraphy is
currently recommended to look for bony disease [1].
MIBG in its most simple form provides 2D planar infor-
mation (scintigraphy). It can, however, be acquired in a
3D format with the resultant Single Positron Emission
Tomography (SPET or SPECT) images providing more
detailed information. Fusing these 3D images with CT
can enable tissue differentiation. Studies comparing
other functional imaging techniques are currently being
undertaken. FDG, fluorodeoxyglucose, is an analogue of
glucose that is a positron emitter. The degree of glucose
metabolism, and thus uptake of FDG, is higher in tu-
mours such as NBL. FDG combined with CT, PET-CT,
allows for more accurate localization of disease. Despite
this, there can be the problem of false-positives and
false-negatives in non-tumour sites [9]. Studies compar-
ing MIBG to FDG-PET have shown that the former can
be sensitive and specific in higher stage disease with FDG-
PET being useful in stage 1 and 2 disease or in MIBG
non-avid tumours [9]. An emerging PET/CT compound is
Ga-68 DOTATATE, which utilizes somatostatin receptor
expression in NBLs, in particular sub-type 2 [10,11].
Gallium-68 is a generator produced positron-emitting iso-
tope that is combined with a chelator, DOT, and an
Figure 2 Coronal T2 MR of a 3 year old boy with extensive abdominal NBL that crosses the midline and is here seen to encase the
aorta (blue arrow).
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binds to somatostatin receptors and can, therefore, be
used for diagnosis and follow-up [10]. DOTATATE is
not necessarily limited to use as a diagnostic agent. A
study by Gains et al combined the use of Ga-68 DOTA-
TATE for assessment and followed this with Lu-177-
DOTATATE for targeted molecular therapy [11]. This
showed promising early results as a feasible agent in a
select patient cohort [11].
Bone marrow biopsy is also necessary, alongside im-
aging, to confirm bony disease [6].
Staging
The International Neuroblastoma Staging System (INSS)
has been used since 1986 to stage NBL [Table 1], how-
ever, there was significant worldwide variability in the
application of this system, which to some extent is
dependent on local protocol and experience [12]. Also, it
is a post-surgical staging system and is thus dependent
on the expertise of the local surgeon. Assessment of riskpre-surgery was recently deemed to need better defining,
with now more reliance placed on pre-operative imaging
[8,9]. The International Neuroblastoma Risk Group
(INRG) was thus established in 2004 to create a more
comprehensive staging system. The INRGSS has 4 sim-
pler stages of disease summarised in Table 2 [13,14].
The INRGSS has not been designed to replace the INSS
and centres will likely use both in the management of
NBL patients [14]. What INRGSS allows is the pre-
surgical assessment of tumours, with imaging making a
significant contribution to this. To enable consistent
reporting, image defined risk factors (IDRFs) have been
identified by the INRG – these describe the relationship
between the tumour and adjacent vascular, major airway
or nervous system structures, which ideally should not
be injured at surgery [6,14].
Image defined risk factors (IDRFs)
The entire number of IDRFs are summarised in Table 3.
They can be simplified as major vascular encasement,
Figure 3 Axial T2 MR of 2 year old girl showing NBL with rib invasion (blue arrow), anterior aortic displacement and encasement
(red arrow) and bilateral pleural effusions.
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ment is defined as 50% or greater encirclement of the
vessel, with the exception of the renal vasculature
where any tumour abutting the renal vessels is regarded
as an IDRF [15].
Preliminary evidence suggests absence of IDRFs leads
to more complete resection, with the presence of IDRFs
resulting in more post-operative morbidity [16]. It isFigure 4 Axial T2 MR of 3 year old boy showing intraspinal extent of
image (blue arrows).unknown at present if the presence or absence of IDRFs
affects overall survival.
Management
The COG stratify risk as low, intermediate or high based
on prognostic factors and the INSS staging system. Low-
risk patients have a 5-year survival rate > 95% with inter-
mediate and high risk group rates of 90-95% and 40-50%NBL with tumour seen in both neural foramina on this single
Figure 5 Coronal T2 MR of a 2 year old boy showing left-sided NBL mass with bone marrow involvement (blue arrow).
Figure 6 Axial CT of a 2 year old girl showing a left-sided abdominal NBL with evidence of calcification (blue arrows).
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Figure 7 MIBG scintigraphy showing avid uptake at the site of the abdominal NBL with widespread bony metastatic spread.
Table 1 INSS staging system [11]
Tumour stage Description
Stage 1 - Localized tumour with complete gross excision (+/-microscopic residual)
- Ipsilateral lymph nodes negative for tumour
- Nodes attached to and removed with tumour may be positive
Stage 2A - Localized tumour with incomplete gross excision
- Ipsilateral non-adherent lymph nodes negative for tumour
Stage 2B - Localized tumour +/- complete gross excision
- Ipsilateral non-adherent lymph nodes positive for tumour
- Enlarged contralateral lymph nodes negative for tumour
Stage 3 - Unresectable unilateral tumour infiltrating across midline
- +/- Regional lymph node involvement
Stage 4 - Any primary tumour with distant spread to lymph nodes, bone, bone marrow, liver, skin and/or
other organs (except as defined for stage 4S)
Stage 4S - Only for infants <1 year
- Localized primary tumour with disseminated disease limited to skin, liver and/or bone marrow
(marrow involvement < 10% on biopsy and MIBG negative marrow)
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Table 2 INRGSS [11,12]
Tumour
stage
Description
L1 - Local disease with no IDRF
L2 - Local disease with one or more IDRF
M - Distant metastatic disease
MS - Distant metastatic disease confined to skin, liver and/or
bone marrow (<10% involvement) in those under 18 months
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bination of surgery, chemotherapy and radiotherapy,
with additional myeloablative therapy and more recently
also immunotherapy for high-risk disease. The clinical
approach should involve multidisciplinary discussionTable 3 Image defined risk factors [12]
Risk factor Description
Ipsilateral tumour extension within two
body compartments
•Neck-chest
•Chest-abdomen
•Abdomen-pelvis
Neck •Tumour encasing car
•Tumour extending to
•Tumour compressing
Cervico-thoracic junction •Tumour encasing bra
•Tumour encasing sub
•Tumour compressing
Thorax •Tumour encasing the
•Tumour compressing
•Lower mediastinal tu
Thoraco-abdominal •Tumour encasing the
Abdomen/pelvis •Tumour infiltrating th
•Tumour encasing bra
•Tumour encasing the
•Tumour invading on
•Tumour encasing the
•Tumour encasing the
•Pelvic tumour crossin
Intraspinal tumour extension whatever the
location provided that:
•More than one third
leptomeningeal space
Infiltration of adjacent organs/structures •Pericardium
•Diaphragm
•Kidney
•Liver
•Duodeno-pancreatic
•Mesentery
Conditions to be recorded, but not
considered IDRFs
•Multifocal primary tu
•Pleural effusion, with
•Ascites, with or withofollowing thorough risk-assessment. Low risk patients
with local tumour masses should have them surgically
resected. This may occur following chemotherapy to try
and shrink the mass, ensuring full resection [8]. Inter-
mediate risk patients have chemotherapy followed by
surgery [17]. High-risk patients have a more intensive
chemotherapy course followed by resection then myeloa-
blative chemotherapy [16]. Radiotherapy directly to the
mass is also routinely administered in high-risk tumours
post-chemotherapy [8].
Nephroblastoma (Wilms Tumour)
Background
Nephroblastoma is more commonly known as a Wilms
tumour after Dr Max Wilms, the German surgeon whootid and/or vertebral artery and/or internal jugular vein
base of skull
the trachea
chial plexus roots
clavian vessels and/or vertebral and/or carotid artery
the trachea
aorta and/or major branches
the trachea and/or principal bronchi
mour, infiltrating the costo-vertebral junction between T9 and T12
aorta and/or vena cava
e porta hepatis and/or the hepatoduodenal ligament
nches of the superior mesenteric artery at the mesenteric root
origin of the coeliac axis, and/or of the superior mesenteric artery
e or both renal pedicles
aorta and/or vena cava
iliac vessels
g the sciatic notch
of the spinal canal in the axial plane is invaded and/or the perimedullary
s are not visible and/or the spinal cord signal is abnormal
block
mours
or without malignant cells
ut malignant cells
Dumba et al. Cancer Imaging  (2015) 15:5 Page 9 of 14first described it in 1899. It is the most common renal
malignancy in childhood and accounts overall for 6% of
malignancies in children [18]. After hydronephrosis and
multicystic dysplastic kidney, it is the most common
cause of a renal mass in a child [19]. It typically occurs
in childhood with a peak incidence between 3–4 years.
It is a little more prevalent in people of African descent.
Wilms tumour is an undifferentiated mesodermal
tumour, containing a variable amount of embryonic renal
elements (blastema, epithelium and stroma) [20]. There are
now two distinct histopathological types based on progno-
sis – favourable (over 90%) and unfavourable (6-10%). The
anaplastic and sarcomatous variants are the unfavourable
histologies associated with a poorer outcome [21].
Associations and risk factors
Nephroblastomatosis, which consists of immature meta-
nephric tissue (nephrogenic rests), is considered a pre-
cursor to Wilms tumour [Figure 8]. The exact risk of
development of Wilms tumour on a background of
nephroblastomatosis is unclear, however. If a removed
kidney containing a Wilms tumour is found to have
nephroblastomatosis, there is a 20% chance of develop-
ing a Wilms tumour in the contralateral kidney [22].
Syndromes associated with nephroblastomatosis include
trisomies 13 and 18, Beckwith-Weidemann (10-20% risk
of Wilms; gigantism, macroglossia, omphalocoele and
genitourinary abnormalities, associated with an abnormal
WT2 gene on 11p15) and Drash syndromes (ambiguous
genitalia and progressive renal failure in genotypic males,
associated with an abnormal WT1 gene on 11p13).
Other conditions associated with Wilms tumour in-
clude hemihypertrophy (WT2 gene), WAGR syndromeFigure 8 Axial T2 MR of a 4 year old boy with right-sided Wilms tumo(Wilms tumour, aniridia, genitourinary abnormalities and
mental retardation, WT1 gene), sporadic non-familial
aniridia, neurofibromatosis type 1 and cerebral gigantism
(Sotos syndrome) [19,22].
Clinical features
Presentation is usually with a large, painless abdominal
mass and very little in the way of constitutional symp-
toms [20]. Up to 10% are discovered incidentally after
trauma, 25% have microscopic haematuria and 25%
manifest with hypertension secondary to renin produc-
tion [20].
Diagnosis
Plain abdominal radiographs are non-specific for Wilms
tumours. If performed, a feature that may be seen is a
soft tissue mass displacing loops of bowel.
Imaging and diagnosis of Wilms tumour generally be-
gins with US [Figure 9], which can evaluate whether the
mass is truly intra- or extra-renal and whether it is solid
or cystic [23]. It should be noted that often Wilms le-
sions appear to have large hypoechoic areas due to cen-
tral necrosis and cyst formation. Hyperechoic areas may
represent areas of fat, calcification or haemorrhage. It
may also appear less commonly as a solid spherical mass
[19]. In contrast to neuroblastoma, vessels are displaced
rather than encased as the tumour directly displaces ad-
jacent structures as it grows. Vascular invasion is esti-
mated to occur in approximately 5-10% of cases [24]. US
is useful for the assessment of caval patency and IVC
tumour thrombus and is the preferred modality for this
in our experience. In one North American study,
contrast-enhanced CT was more sensitive to disease inur and left-sided nephroblastomatosis (blue arrow).
Figure 9 Ultrasound abdomen of a 4 year old boy with a left-sided Wilms tumour, presenting here unusually as a solid uniform mass.
Figure 10 Coronal T2 fat-saturated MR of 3 year old boy showing a right sided Wilms tumour with the ‘claw sign’ of normal renal tissue
(blue arrow) surrounding the tumour.
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if a staging CT has already confirmed the presence of
thrombus [25]. Renal vein thrombus may be more diffi-
cult to evaluate or exclude with US, and CT or MRI
tend to be easier to interpret in this setting.
Although yet to be conclusively shown to be superior to
CT, the preferred imaging modality at diagnosis is now
without doubt contrast-enhanced MRI, in these children
with such a favourable long-term outcome. Like CT,
MRI can also readily demonstrate the ‘claw sign’ of nor-
mal renal tissue around the tumour [Figure 10]. The
tumour extent is easily visualised on non-contrast T1W
and T2W sequences, but small bilateral tumours and
foci of nephroblastomatosis are often best seen after gado-
linium administration. Isovolumetric sequences, allowing
reconstructions in other orthogonal planes, can be par-
ticularly helpful with bilateral disease [Figure 11] when
renal preservation surgery is the operative strategy.
MR findings in Wilms tumour are low signal intensity
on T1W, with variable/high signal intensity on T2W
[26]. Foci of nephroblastomatosis may be small cystic le-
sions, hyperintense on T2W but sclerotic nephrogenic
rests may appear fibrotic, being relatively hypointenseFigure 11 Coronal T2 MR of a 4 year old girl with bilateral Wilms tumon T2W sequences. The non-cystic components of the
Wilms mass typically show restricted diffusion on DWI.
Some surgeons may quite reasonably prefer later pre-
operative CT prior to surgery, and this would generally
be a local preference [Figure 12]. Post-treatment surveil-
lance for bilateral disease should be with MRI and not
CT to reduce the radiation burden in these children the
vast majority of whom have a good long-term prognosis
[27], but some institutions may image post-operatively
with CT at the surgeon’s request.
There is continuing uncertainty about the role of pre-
operative staging chest CT in the diagnosis of small pul-
monary metastases in Wilms tumour. Certainly CT is
superior to chest radiography for the detection of small
lesions, but these may not always represent metastases.
For patients with unilateral Wilms tumour with lung le-
sions only visible on chest CT, not seen on plain chest
radiographs (but deemed metastases and treated as
such), their overall survival and event-free survival was
no different to those patients whose lung lesions were
not deemed metastatic [28]. However, the role of chest
CT is not controversial in patients who post-operatively
are found to have unfavourable histology or stage IIIours, more cystic on the left.
Figure 12 Axial CT of a 3 year old boy with right-sided Wilms tumour, again demonstrating the ‘claw sign’ (blue arrow).
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prove overall survival in these patients [28].
PET-CT currently has no role in the initial diagnosis
of Wilms tumours as the general prognosis is excellent
and radiation exposure should be minimised. In patients
who have relapsed, routine PET-CT may be of benefit as
their prognosis is more guarded and the best chance of
cure is at the first relapse. Accurate staging and discov-
ery of the full extent of metastatic disease would there-
fore aid survival.
Wilms tumour classically follows the “rule of 10’s”: up to
10% may have unfavourable histology, 10% are bilateral,
10% have vascular invasion, 10% have calcifications on CT
and 10% have pulmonary metastases at presentation [19].Table 4 Children’s oncology group staging system for Wilms
Stage Location
Stage I Confined to kidney with capsule intact
Stage II Local spread beyond kidney including renal vein i
This includes tumour with local spillage confined
Stage III Residual disease confined to the abdomen, includ
a) lymph node involvement
b) diffuse peritoneal contamination by growth or
c) positive surgical resection margins
d) residual non-resected tumour
Stage IV Haematogenous metastases
Stage V Bilateral renal involvementStaging
Staging of Wilms has been developed by the National
Wilms Tumour Study (NWTS) and the current staging
system is used by the COG (Table 4). The same post-
operative staging system is utilised in European SIOP
studies, albeit after courses of pre-operative chemotherapy
rather than with upfront surgery as in COG studies. Ac-
curate staging, especially the presence or absence of nodal
disease, is vital in Wilms tumour to ensure appropriate
management pathways are adhered to [23].
Management
A unilateral Wilms tumour is treated with nephrectomy.
Neoadjuvant chemotherapy is useful to shrink tumour sizetumour
Management
Complete resection
nvolvement.
to the flank
Complete resection still possible
ing: Complete resection NOT possible
spillage
Complete resection NOT possible
Each kidney should be staged individually
Table 5 Summary of key differences between abdominal neuroblastoma and Wilms tumour
Parameter Neuroblastoma Wilms tumour
Age Younger age group: < 2 years of age commonly Slightly older age group : peak 3 - 4 years of age
Presentation Painful abdominal mass Painless abdominal mass
Calcification Calcification very common: 80-90% Calcification uncommon: 10%
Tumour composition Solid mass lesion, rarely cystic components on US Often cystic components at US
Tumour margin Poorly marginated mass that may extend up into chest Well circumscribed mass - claw sign demonstrating it
arises from the kidney
Adrenal NBL displaces the kidney
Vessel involvement Encases vascular structures but does not invade them -
elevates the aorta away from the vertebral column
Displaces adjacent structures – invades the vasculature
with extension into renal vein/IVC
Metastatic sites Bone/bone marrow (common) Lung (common)
Liver Liver
Lung/pleura Local lymph nodes
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plication of this differs. SIOP prefer pre-operative chemo-
therapy as surgery is made easier as a consequence and
there is less risk of tumour spillage. The result is less stage
III disease, thus some patients are down-staged. Radio-
therapy is indicated for local stage III, so down-staged pa-
tients avoid this and the long-term post-radiotherapy
sequelae. There are slightly higher local relapse rates
reported in SIOP studies, but these radiotherapy naïve
patients do appear to have high salvage rates [29] The
American approach is initial surgery and then chemother-
apy after post-surgical staging.
In children with bilateral disease, the therapeutic ap-
proach and philosophy are very different. Renal preser-
vation surgery becomes paramount. Pre-operative
chemotherapy is vital as each kidney is ultimately
staged separately. Hemi-nephrectomy, wedge resections
and nephron-sparing surgery require accurate pre-
operative imaging. The surgical approach in bilateral
disease aims to spare any normal renal parenchyma
where possible.
Treatment of Wilms tumour is hailed as one of the
greatest success stories in modern oncology. Results
from the NWTS Group has found overall 10-year sur-
vival rates for favourable histology of 96-89% for stages
I-III disease (82-49% for unfavourable histology), 81%
for stage IV disease (18% for unfavourable histology) and
78% for stage V disease [23].Conclusion
Neuroblastoma and Wilms tumour are both relatively
common abdominal childhood cancers. Some notable
key differences are summarised in Table 5. Considering
these factors with new presentations can be helpful with
early management strategies, and in initial discussions
with a family who have a child with a newly diagnosed
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